<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02045823</url>
  </required_header>
  <id_info>
    <org_study_id>Maestro2000AP</org_study_id>
    <nct_id>NCT02045823</nct_id>
  </id_info>
  <brief_title>OCT Agreement and Precision Study</brief_title>
  <official_title>Topcon 3D OCT-1 Maestro and 3D OCT-2000 Optical Coherence Tomography Systems: Agreement and Precision Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topcon Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topcon Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate clinical substantial equivalence of 3D OCT-1 Maestro as comparable to the
      commercially available iVue and NW-300. Also, to demonstrate clinical substantial equivalence
      of 3D OCT-2000 Maestro as comparable to the commercially available NW-300.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal Thickness</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Normal Eyes</condition>
  <condition>Eyes With Glaucoma</condition>
  <condition>Eyes With Retinal Disease</condition>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <description>Normal results from clinical exam and free of ocular pathology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma</arm_group_label>
    <description>Clinical exam with results consistent with glaucoma and visual field defects consistent with glaucoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retina</arm_group_label>
    <description>clinical exam with results consistent with retina pathology</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects that are Normal, or shows signs of Glaucoma, or Retinal Ocular Pathology.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Normal Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to Criteria
             participate as evidenced by signing the informed consent

          3. Subjects presenting at the site with normal eyes (eyes without pathology)

          4. lOPs 21mmHg bilaterally

          5. BCVA 20/40 or better (each eye)

          6. Both eyes must be free of eye disease

        Exclusion Criteria for Normal Group

          1. Subjects unable to tolerate ophthalmic imaging

          2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          3. HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT
             'Outside Normal Limits' and/or PSD &lt; 5%

          4. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on
             manufacturer's recommendation), defined as fixation losses&gt; 33% or false positives&gt;
             25%, or false negatives&gt; 25%

          5. Presence of any ocular pathology except for cataract

          6. Previous ocular surgery or laser treatment, other than uncomplicated refractive
             procedure or cataract surgery, performed within six months prior to study scanning

          7. Narrow angle

          8. History of leukemia, dementia or multiple sclerosis

          9. Concomitant use of hydroxychloroquine and chloroquine

        Inclusion Criteria for Glaucoma Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

          3. Subjects presenting at the site with glaucoma

          4. BCVA 20/40 or better in the study eye

          5. HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT
             'Outside Normal Limits' and/or PSD &lt; 5% in the study eye

        Exclusion Criteria for Glaucoma Group

          1. Subjects unable to tolerate ophthalmic imaging

          2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          3. HFA visual field (24-2 Sita Standard, white on white) result unreliable, defined as
             fixation losses&gt; 33% or false positives&gt; 25%, or false negatives &gt; 25% in the study
             eye

          4. Presence of any ocular pathology except glaucoma in the study eye

          5. Previous ocular surgery or laser treatment, other than uncomplicated refractive
             procedure or cataract surgery, performed within six months prior to study scanning in
             the study eye

          6. History of leukemia, dementia or multiple sclerosis

          7. Concomitant use of hydroxychloroquine and chloroquine

        Inclusion Criteria for Retina Disease Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

          3. Subjects presenting at the site with retinal disease

          4. lOP&lt;= 21mmHg in the study eye

          5. BCVA 20/400 or better in the study eye

          6. Diagnosis of some type of retinal pathology by investigator, may include, but not
             limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy,
             Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others

        Exclusion Criteria for Retinal Disease Group

          1. Subjects unable to tolerate ophthalmic imaging

          2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          3. Presence of glaucoma or any ocular pathology other than a Retinal pathology (e.g.,
             cornea pathology) in the study eye

          4. Previous ocular surgery or laser treatment other than uncomplicated refractive
             procedure or cataract surgery, performed within six months prior to study scanning in
             the study eye

          5. Narrow angle in the study eye

          6. History of leukemia, dementia or multiple sclerosis

          7. Concomitant use of hydroxychloroquine and chloroquine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Sinai, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Topcon Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York VA</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2014</study_first_posted>
  <last_update_submitted>July 28, 2014</last_update_submitted>
  <last_update_submitted_qc>July 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

